Annexon reports fourth quarter and year-end 2024 financial results, portfolio progress and key anticipated milestones

Robust, consistent phase 3 data and real-world evidence outcomes support anx005 as potential first targeted therapy for gbs; pre-bla meeting targeted for 1h 2025 ahead of planned biologics license application (bla) submission established groundbreaking global registration path for anx007 to be potential first vision-preserving treatment for dry amd with ga in europe and u.s.; topline phase 3 archer ii data expected second half 2026 first-in-kind oral c1s inhibitor poc trial ongoing with dosing in three patients with cold agglutin disease; expanded anx1502 dataset to include up to seven patients expected mid-2025 strong balance sheet with cash, cash equivalents, and short-term investments of approximately $312 million as of december 31, 2024, and anticipated runway into second half 2026 brisbane, calif., march 03, 2025 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2024 financial results.
ANNX Ratings Summary
ANNX Quant Ranking